A West Virginia District Court ruled that a key patent covering Biogen's multiple sclerosis medicine Tecfidera is invalid, a win for the generics company Mylan (NASDAQ:MYL), which could have a copycat on the market as early as next year, according to an article in BioPharma Dive.Shortly thereafter, Biogen made a 180-degree turn and said that based on additional data that showed aducanumab was effective against Alzheimer's, it would file for U.S. Food and Drug Administration approval.